Plasma gelsolin: Indicator of inflammation and its potential as a diagnostic tool and therapeutic target

International Journal of Molecular Sciences

Volumn 19, Issue 9, 2018, Pages

  Piktel, Ewelina ^a   Levental, Ilya ^b   Durnaś, Bonita ^c   Janmey, Paul A ^d   Bucki, Robert ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c JAN KOCHANOWSKI UNIVERSITY   (Poland)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Actin; Biomarker; Extracellular recombinant gelsolin; Inflammation; Plasma gelsolin

Indexed keywords

CHLOROQUINE; FIBRIN; FIBRONECTIN; GELSOLIN; INTERLEUKIN 4; MATRIX METALLOPROTEINASE; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AMYLOIDOSIS; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; BRAIN INJURY; BURN; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; DIABETES MELLITUS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJURY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LUNG INJURY; MALIGNANT NEOPLASM; NEUROLOGIC DISEASE; OSTEOCLASTOGENESIS; PHAGOCYTOSIS; PNEUMONIA; PREECLAMPSIA; PREGNANCY; REVIEW; RHABDOMYOLYSIS; SENSITIVITY AND SPECIFICITY; SEPSIS; STREPTOCOCCUS PNEUMONIAE; STRESS; WESTERN BLOTTING; WOUND HEALING; ANIMAL; BLOOD; DISEASE MODEL; DISEASE PREDISPOSITION; FEMALE; GENETICS; MALE; METABOLISM; NEOPLASM; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FEMALE; GELSOLIN; HUMANS; INFLAMMATION; MALE; NEOPLASMS; PREGNANCY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85052496534     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19092516     Document Type: Review

References (195)

1. Yin, H.L.; Kwiatkowski, D.J.; Mole, J.E.; Cole, F.S. Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J. Biol. Chem. 1984, 259, 5271–5276. [PubMed]
2. Bucki, R.; Levental, I.; Kulakowska, A.; Janmey, P.A. Plasma gelsolin: Function, prognostic value, and potential therapeutic use. Curr. Protein Pept. Sci. 2008, 9, 541–551. [CrossRef] [PubMed]
3. Silacci, P.; Mazzolai, L.; Gauci, C.; Stergiopulos, N.; Yin, H.L.; Hayoz, D. Gelsolin superfamily proteins: Key regulators of cellular functions. Cell Mol. Life Sci. 2004, 61, 2614–2623. [CrossRef] [PubMed]
4. Allen, P.G. Functional consequences of disulfide bond formation in gelsolin. FEBS Lett. 1997, 401, 89–94. [CrossRef]
5. Wen, D.; Corina, K.; Chow, E.P.; Miller, S.; Janmey, P.A.; Pepinsky, R.B. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 1996, 35, 9700–9709. [CrossRef] [PubMed]
6. Vouyiouklis, D.A.; Brophy, P.J. A novel gelsolin isoform expressed by oligodendrocytes in the central nervous system. J. Neurochem. 1997, 69, 995–1005. [CrossRef] [PubMed]
7. Cowin, A.J.; Lei, N.; Franken, L.; Ruzehaji, N.; Offenhäuser, C.; Kopecki, Z.; Murray, R.Z. Lysosomal secretion of flightless i upon injury has the potential to alter inflammation. Commun. Integr. Biol. 2012, 5, 546–549. [CrossRef] [PubMed]
8. Smith, D.B.; Janmey, P.A.; Herbert, T.J.; Lind, S.E. Quantitative measurement of plasma gelsolin and its incorporation into fibrin clots. J. Lab. Clin. Med. 1987, 110, 189–195. [PubMed]
9. Kwiatkowski, D.J.; Mehl, R.; Izumo, S.; Nadal-Ginard, B.; Yin, H.L. Muscle is the major source of plasma gelsolin. J. Biol. Chem. 1988, 263, 8239–8243. [PubMed]
10. Candiano, G.; Bruschi, M.; Pedemonte, N.; Caci, E.; Liberatori, S.; Bini, L.; Pellegrini, C.; Viganò, M.; O’Connor, B.J.; Lee, T.H.; et al. Gelsolin secretion in interleukin-4-treated bronchial epithelia and in asthmatic airways. Am. J. Respir. Crit. Care Med. 2005, 172, 1090–1096. [CrossRef] [PubMed]
11. Jordan, J.R.; Moore, E.E.; Damle, S.S.; Eckels, P.; Johnson, J.L.; Roach, J.P.; Redzic, J.S.; Hansen, K.C.; Banerjee, A. Gelsolin is depleted in post-shock mesenteric lymph. J. Surg. Res. 2007, 143, 130–135. [CrossRef] [PubMed]
12. Grinnell, F.; Baxter, C.R.; Zhu, M.; Yin, H.L. Detection of the actin scavenger system in burn wound fluid. Wound Repair. Regen. 1993, 1, 236–243. [CrossRef] [PubMed]
13. Yuan, X.; Desiderio, D.M. Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. J. Proteome Res. 2003, 2, 476–487. [CrossRef] [PubMed]
14. Jagadish, T.; Pottiez, G.; Fox, H.S.; Ciborowski, P. Plasma gelsolin accumulates in macrophage nodules in brains of simian immunodeficiency virus infected rhesus macaques. J. Neurovirol. 2012, 18, 113–119. [CrossRef] [PubMed]
15. Sezen, D.; Bongiovanni, A.M.; Gelber, S.; Perni, U.; Hutson, J.M.; Skupski, D.; Witkin, S.S. Gelsolin down-regulates lipopolysaccharide-induced intraamniotic tumor necrosis factor-alpha production in the midtrimester of pregnancy. Am. J. Obstet. Gynecol. 2009, 200, 191.e1–191.e4. [CrossRef] [PubMed]
16. Kwiatkowski, D.J. Functions of gelsolin: Motility, signaling, apoptosis, cancer. Curr. Opin. Cell Biol. 1999, 11, 103–108. [CrossRef]
17. Wang, H.; Cheng, B.; Chen, Q.; Wu, S.; Lv, C.; Xie, G.; Jin, Y.; Fang, X. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit. Care 2008, 12, R106. [CrossRef] [PubMed]
18. Mounzer, K.C.; Moncure, M.; Smith, Y.R.; Dinubile, M.J. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am. J. Respir. Crit. Care Med. 1999, 160, 1673–1681. [CrossRef] [PubMed]
19. Bucki, R.; Janmey, P.A. Extracellular aggregation of polyelectrolytes escaped from the cell interior: Mechanisms and physiological consequences. Curr. Opin. Colloid Interface Sci. 2016, 26, 84–89. [CrossRef]
20. Lee, W.M.; Galbraith, R.M. The extracellular actin-scavenger system and actin toxicity. N. Engl. J. Med. 1992, 326, 1335–1341. [PubMed]
21. Haddad, J.G.; Harper, K.D.; Guoth, M.; Pietra, G.G.; Sanger, J.W. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc. Natl. Acad. Sci. USA 1990, 87, 1381–1385. [CrossRef] [PubMed]
22. Basaraba, R.J.; Byerly, A.N.; Stewart, G.C.; Mosier, D.A.; Fenwick, B.W.; Chengappa, M.M.; Laegreid, W.W. Actin enhances the haemolytic activity of escherichia coli. Microbiology 1998, 1845–1852. [CrossRef] [PubMed]
23. Vasconcellos, C.A.; Lind, S.E. Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin d-binding protein. Blood 1993, 82, 3648–3657. [PubMed]
24. Scarborough, V.D.; Bradford, H.R.; Ganguly, P. Aggregation of platelets by muscle actin. A multivalent interaction model of platelet aggregation by adp. Biochem. Biophys. Res. Commun. 1981, 100, 1314–1319. [CrossRef]
25. Bucki, R.; Byfield, F.J.; Kulakowska, A.; McCormick, M.E.; Drozdowski, W.; Namiot, Z.; Hartung, T.; Janmey, P.A. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J. Immunol. 2008, 181, 4936–4944. [CrossRef] [PubMed]
26. Osborn, T.M.; Dahlgren, C.; Hartwig, J.H.; Stossel, T.P. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am. J. Physiol. Cell. Physiol. 2007, 292, C1323–C1330. [CrossRef] [PubMed]
27. Bucki, R.; Kulakowska, A.; Byfield, F.J.; Zendzian-Piotrowska, M.; Baranowski, M.; Marzec, M.; Winer, J.P.; Ciccarelli, N.J.; Górski, J.; Drozdowski, W.; et al. Plasma gelsolin modulates cellular response to sphingosine 1-phosphate. Am. J. Physiol. Cell. Physiol. 2010, 299, C1516–C1523. [CrossRef] [PubMed]
28. Lind, S.E.; Janmey, P.A. Human plasma gelsolin binds to fibronectin. J. Biol. Chem. 1984, 259, 13262–13266. [PubMed]
29. Ruzehaji, N.; Mills, S.J.; Melville, E.; Arkell, R.; Fitridge, R.; Cowin, A.J. The influence of flightless i on toll-like-receptor-mediated inflammation in a murine model of diabetic wound healing. Biomed. Res. Int. 2013, 2013, 389792. [CrossRef] [PubMed]
30. Pellieux, C.; Desgeorges, A.; Pigeon, C.H.; Chambaz, C.; Yin, H.; Hayoz, D.; Silacci, P. Cap g, a gelsolin family protein modulating protective effects of unidirectional shear stress. J. Biol. Chem. 2003, 278, 29136–29144. [CrossRef] [PubMed]
31. Hassanpour, S.; Jiang, H.; Wang, Y.; Kuiper, J.W.; Glogauer, M. The actin binding protein adseverin regulates osteoclastogenesis. PLoS ONE 2014, 9, e109078. [CrossRef] [PubMed]
32. Witke, W.; Sharpe, A.H.; Hartwig, J.H.; Azuma, T.; Stossel, T.P.; Kwiatkowski, D.J. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 1995, 81, 41–51. [CrossRef]
33. Furukawa, K.; Fu, W.; Li, Y.; Witke, W.; Kwiatkowski, D.J.; Mattson, M.P. The actin-severing protein gelsolin modulates calcium channel and nmda receptor activities and vulnerability to excitotoxicity in hippocampal neurons. J. Neurosci. 1997, 17, 8178–8186. [CrossRef] [PubMed]
34. Gupta, A.K.; Parasar, D.; Sagar, A.; Choudhary, V.; Chopra, B.S.; Garg, R.; Khatri, N. Analgesic and anti-inflammatory properties of gelsolin in acetic acid induced writhing, tail immersion and carrageenan induced paw edema in mice. PLoS ONE 2015, 10, e0135558. [CrossRef] [PubMed]
35. Li-ChunHsieh, K.; Schob, S.; Zeller, M.W.; Pulli, B.; Ali, M.; Wang, C.; Chiou, T.T.; Tsang, Y.M.; Lee, P.S.; Stossel, T.P.; et al. Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis. J. Neuroimmunol 2015, 287, 36–42. [PubMed]
36. Khatri, N.; Sagar, A.; Peddada, N.; Choudhary, V.; Chopra, B.S.; Garg, V.; Garg, R. Plasma gelsolin levels decrease in diabetic state and increase upon treatment with f-actin depolymerizing versions of gelsolin. J. Diabetes. Res. 2014, 2014, 152075. [CrossRef] [PubMed]
37. Chellaiah, M.; Kizer, N.; Silva, M.; Alvarez, U.; Kwiatkowski, D.; Hruska, K.A. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J. Cell. Biol. 2000, 148, 665–678. [CrossRef] [PubMed]
38. Rothenbach, P.A.; Dahl, B.; Schwartz, J.J.; O’Keefe, G.E.; Yamamoto, M.; Lee, W.M.; Horton, J.W.; Yin, H.L.; Turnage, R.H. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J. Appl. Physiol. (1985) 2004, 96, 25–31. [CrossRef] [PubMed]
39. Christofidou-Solomidou, M.; Scherpereel, A.; Solomides, C.C.; Muzykantov, V.R.; Machtay, M.; Albelda, S.M.; DiNubile, M.J. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung 2002, 180, 91–104. [CrossRef] [PubMed]
40. Xu, J.F.; Liu, W.G.; Dong, X.Q.; Yang, S.B.; Fan, J. Change in plasma gelsolin level after traumatic brain injury. J. Trauma. Acute. Care Surg. 2012, 72, 491–496. [CrossRef] [PubMed]
41. Dahl, B.; Schiødt, F.V.; Ott, P.; Gvozdenovic, R.; Yin, H.L.; Lee, W.M. Plasma gelsolin is reduced in trauma patients. Shock 1999, 12, 102–104. [CrossRef] [PubMed]
42. Li, M.; Cui, F.; Cheng, Y.; Han, L.; Wang, J.; Sun, D.; Liu, Y.L.; Zhou, P.K.; Min, R. Gelsolin: Role of a functional protein in mitigating radiation injury. Cell. Biochem. Biophys. 2015, 71, 389–396. [CrossRef] [PubMed]
43. Rithidech, K.N.; Reungpatthanaphong, P.; Tungjai, M.; Jangiam, W.; Honikel, L.; Whorton, E.B. Persistent depletion of plasma gelsolin (pgsn) after exposure of mice to heavy silicon ions. Life Sci. Space. Res. 2018, 17, 83–90. [CrossRef] [PubMed]
44. Suhler, E.; Lin, W.; Yin, H.L.; Lee, W.M. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit. Care Med. 1997, 25, 594–598. [CrossRef] [PubMed]
45. Erukhimov, J.A.; Tang, Z.L.; Johnson, B.A.; Donahoe, M.P.; Razzack, J.A.; Gibson, K.F.; Lee, W.M.; Wasserloos, K.J.; Watkins, S.A.; Pitt, B.R. Actin-containing sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am. J. Respir. Crit. Care Med. 2000, 162, 288–294. [CrossRef] [PubMed]
46. Lee, P.S.; Drager, L.R.; Stossel, T.P.; Moore, F.D.; Rogers, S.O. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann. Surg. 2006, 243, 399–403. [CrossRef] [PubMed]
47. Xianhui, L.; Pinglian, L.; Xiaojuan, W.; Wei, C.; Yong, Y.; Feng, R.; Peng, S.; Gang, X. The association between plasma gelsolin level and prognosis of burn patients. Burns 2014, 40, 1552–1555. [CrossRef] [PubMed]
48. Huang, L.F.; Yao, Y.M.; Li, J.F.; Dong, N.; Liu, C.; Yu, Y.; He, L.X.; Sheng, Z.Y. Reduction of plasma gelsolin levels correlates with development of multiple organ dysfunction syndrome and fatal outcome in burn patients. PLoS ONE 2011, 6, e25748. [CrossRef] [PubMed]
49. Chen, L.; Meng, K.; Su, W.; Fu, Y. The effect of continuous sedation therapy on immunomodulation, plasma levels of antioxidants, and indicators of tissue repair in post-burn sepsis patients. Cell. Biochem. Biophys. 2015, 73, 473–478. [CrossRef] [PubMed]
50. Jin, Y.; Li, B.Y.; Qiu, L.L.; Ling, Y.R.; Bai, Z.Q. Decreased plasma gelsolin is associated with 1-year outcome in patients with traumatic brain injury. J. Crit. Care 2012, 27, e521–e526. [CrossRef] [PubMed]
51. Shi, S.; Chen, C.; Zhao, D.; Liu, X.; Cheng, B.; Wu, S.; Lin, R.; Tan, L.; Fang, X.; Shu, Q. The role of plasma gelsolin in cardiopulmonary bypass induced acute lung injury in infants and young children: A. pilot study. BMC. Anesthesiol 2014, 14, 67. [CrossRef] [PubMed]
52. DiNubile, M.J.; Stossel, T.P.; Ljunghusen, O.C.; Ferrara, J.L.; Antin, J.H. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood 2002, 100, 4367–4371. [CrossRef] [PubMed]
53. Ito, H.; Kambe, H.; Kimura, Y.; Nakamura, H.; Hayashi, E.; Kishimoto, T.; Kishimoto, S.; Yamamoto, H. Depression of plasma gelsolin level during acute liver injury. Gastroenterology 1992, 102, 1686–1692. [CrossRef]
54. Halis, H.; Gunes, T.; Korkut, S.; Saraymen, B.; Şen, A.; Bastug, O.; Öztürk, A.; Kurtoğlu, S. In the diagnosis of neonatal sepsis importance of gelsolin and relationship with mortality and morbidity. Med. Hypotheses 2016, 94, 77–80. [CrossRef] [PubMed]
55. Lee, P.S.; Patel, S.R.; Christiani, D.C.; Bajwa, E.; Stossel, T.P.; Waxman, A.B. Plasma gelsolin depletion and circulating actin in sepsis: A. pilot study. PLoS ONE 2008, 3, e3712. [CrossRef] [PubMed]
56. Smith, D.B.; Janmey, P.A.; Sherwood, J.A.; Howard, R.J.; Lind, S.E. Decreased plasma gelsolin levels in patients with plasmodium falciparum malaria: A consequence of hemolysis? Blood 1988, 72, 214–218. [PubMed]
57. Kassa, F.A.; Shio, M.T.; Bellemare, M.J.; Faye, B.; Ndao, M.; Olivier, M. New inflammation-related biomarkers during malaria infection. PLoS ONE 2011, 6, e26495. [CrossRef] [PubMed]
58. Marrocco, C.; Rinalducci, S.; Mohamadkhani, A.; D’Amici, G.M.; Zolla, L. Plasma gelsolin protein: A candidate biomarker for hepatitis b-associated liver cirrhosis identified by proteomic approach. Blood Transfus. 2010, 8, s105–s112. [PubMed]
59. Rozek, W.; Ricardo-Dukelow, M.; Holloway, S.; Gendelman, H.E.; Wojna, V.; Melendez, L.M.; Ciborowski, P. Cerebrospinal fluid proteomic profiling of hiv-1-infected patients with cognitive impairment. J. Proteome Res. 2007, 6, 4189–4199. [CrossRef] [PubMed]
60. Wiederin, J.; Rozek, W.; Duan, F.; Ciborowski, P. Biomarkers of hiv-1 associated dementia: Proteomic investigation of sera. Proteome. Sci. 2009, 7, 8. [CrossRef] [PubMed]
61. Osborn, T.M.; Verdrengh, M.; Stossel, T.P.; Tarkowski, A.; Bokarewa, M. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res. Ther. 2008, 10, R117. [CrossRef] [PubMed]
62. Stalmach, A.; Johnsson, H.; McInnes, I.B.; Husi, H.; Klein, J.; Dakna, M.; Mullen, W.; Mischak, H.; Porter, D. Identification of urinary peptide biomarkers associated with rheumatoid arthritis. PLoS ONE 2014, 9, e104625. [CrossRef] [PubMed]
63. Park, Y.J.; Yoo, S.A.; Hwang, D.; Cho, C.S.; Kim, W.U. Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis. Exp. Mol. Med. 2016, 48, e211. [CrossRef] [PubMed]
64. Eke Gungor, H.; Sahiner, U.M.; Karakukcu, C.; Sahiner, N.; Altuner Torun, Y. The plasma gelsolin levels in atopic dermatitis: Effect of atopy and disease severity. Allergol. Immunopathol. (Madr) 2016, 44, 221–225. [CrossRef] [PubMed]
65. Hu, Y.; Hosseini, A.; Kauwe, J.S.; Gross, J.; Cairns, N.J.; Goate, A.M.; Fagan, A.M.; Townsend, R.R.; Holtzman, D.M. Identification and validation of novel csf biomarkers for early stages of alzheimer’s disease. Proteomics. Clin. Appl. 2007, 1, 1373–1384. [CrossRef] [PubMed]
66. Kułakowska, A.; Zajkowska, J.M.; Ciccarelli, N.J.; Mroczko, B.; Drozdowski, W.; Bucki, R. Depletion of plasma gelsolin in patients with tick-borne encephalitis and lyme neuroborreliosis. Neurodegener Dis. 2011, 8, 375–380. [CrossRef] [PubMed]
67. Kułakowska, A.; Ciccarelli, N.J.; Wen, Q.; Mroczko, B.; Drozdowski, W.; Szmitkowski, M.; Janmey, P.A.; Bucki, R. Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis. BMC. Neurol. 2010, 10, 107.
68. Zhao, D.Q.; Wang, K.; Zhang, H.D.; Li, Y.J. Significant reduction of plasma gelsolin levels in patients with intracerebral hemorrhage. Clin. Chim. Acta. 2013, 415, 202–206. [CrossRef] [PubMed]
69. Chou, S.H.; Lo, E.H.; Ning, M. Plasma-type gelsolin in subarachnoid hemorrhage: Novel biomarker today, therapeutic target tomorrow? Crit. Care 2014, 18, 101. [CrossRef] [PubMed]
70. Chou, S.H.; Lee, P.S.; Konigsberg, R.G.; Gallacci, D.; Chiou, T.; Arai, K.; Simmons, S.; Bauer, D.; Feske, S.K.; Lo, E.H.; et al. Plasma-type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke 2011, 42, 3624–3627. [CrossRef] [PubMed]
71. Tsai, M.H.; Wu, C.C.; Peng, P.H.; Liang, Y.; Hsiao, Y.C.; Chien, K.Y.; Chen, J.T.; Lin, S.J.; Tang, R.P.; Hsieh, L.L.; et al. Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. J. Mol. Med. (Berl) 2012, 90, 187–200. [CrossRef] [PubMed]
72. Pan, S.; Chen, R.; Brand, R.E.; Hawley, S.; Tamura, Y.; Gafken, P.R.; Milless, B.P.; Goodlett, D.R.; Rush, J.; Brentnall, T.A. Multiplex targeted proteomic assay for biomarker detection in plasma: A pancreatic cancer biomarker case study. J. Proteome Res. 2012, 11, 1937–1948. [CrossRef] [PubMed]
73. Scumaci, D.; Tammè, L.; Fiumara, C.V.; Pappaianni, G.; Concolino, A.; Leone, E.; Faniello, M.C.; Quaresima, B.; Ricevuto, E.; Costanzo, F.S.; et al. Plasma proteomic profiling in hereditary breast cancer reveals a brca1-specific signature: Diagnostic and functional implications. PLoS ONE 2015, 10, e0129762. [CrossRef] [PubMed]
74. Ohnishi, M.; Matsumoto, T.; Nagashio, R.; Kageyama, T.; Utsuki, S.; Oka, H.; Okayasu, I.; Sato, Y. Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: Usefulness of gelsolin protein. Pathol. Int. 2009, 59, 797–803. [CrossRef] [PubMed]
75. Lee, P.S.; Sampath, K.; Karumanchi, S.A.; Tamez, H.; Bhan, I.; Isakova, T.; Gutierrez, O.M.; Wolf, M.; Chang, Y.; Stossel, T.P.; et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J. Am. Soc. Nephrol. 2009, 20, 1140–1148. [CrossRef] [PubMed]
76. Chiou, T.T.; Liao, S.C.; Kao, Y.Y.; Lee, W.C.; Lee, Y.T.; Ng, H.Y.; Lee, P.S.; Lee, C.T. Gelsolin and progression of aortic arch calcification in chronic hemodialysis patients. Int. J. Med. Sci. 2016, 13, 92–98. [CrossRef] [PubMed]
77. Zhang, Q.; Fillmore, T.L.; Schepmoes, A.A.; Clauss, T.R.; Gritsenko, M.A.; Mueller, P.W.; Rewers, M.; Atkinson, M.A.; Smith, R.D.; Metz, T.O. Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes. J. Exp. Med. 2013, 210, 191–203. [CrossRef] [PubMed]
78. Jin, J.; Min, H.; Kim, S.J.; Oh, S.; Kim, K.; Yu, H.G.; Park, T.; Kim, Y. Development of diagnostic biomarkers for detecting diabetic retinopathy at early stages using quantitative proteomics. J. Diabetes Res. 2016, 2016, 6571976. [CrossRef] [PubMed]
79. Nadkarni, N.A.; Rajakumar, A.; Mokhashi, N.; Burke, S.D.; Rana, S.; Salahuddin, S.; Dang, Q.; Thadhani, R.; Krishnan, R.; Stossel, T.P.; et al. Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. Pregnancy Hypertens 2016, 6, 333–339. [CrossRef] [PubMed]
80. Tannetta, D.S.; Redman, C.W.; Sargent, I.L. Investigation of the actin scavenging system in pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod Biol. 2014, 172, 32–35. [CrossRef] [PubMed]
81. Löfberg, M.; Paunio, T.; Tähtelä, R.; Kiuru, S.; Somer, H. Serum gelsolin and rhabdomyolysis. J. Neurol. Sci. 1998, 157, 187–190. [CrossRef]
82. Weeds, A.G.; Gooch, J.; McLaughlin, P.; Maury, C.P. Variant plasma gelsolin responsible for familial amyloidosis (finnish type) has defective actin severing activity. FEBS. Lett 1993, 335, 119–123. [CrossRef]
83. Christofidou-Solomidou, M.; Scherpereel, A.; Solomides, C.C.; Christie, J.D.; Stossel, T.P.; Goelz, S.; DiNubile, M.J. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J. Investig. Med. 2002, 50, 54–60. [CrossRef] [PubMed]
84. Zhang, Q.H.; Chen, Q.; Kang, J.R.; Liu, C.; Dong, N.; Zhu, X.M.; Sheng, Z.Y.; Yao, Y.M. Treatment with gelsolin reduces brain inflammation and apoptotic signaling in mice following thermal injury. J. Neuroinflamm. 2011, 8, 118. [CrossRef] [PubMed]
85. Lee, P.S.; Waxman, A.B.; Cotich, K.L.; Chung, S.W.; Perrella, M.A.; Stossel, T.P. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit. Care Med. 2007, 35, 849–855. [CrossRef] [PubMed]
86. Cohen, T.S.; Bucki, R.; Byfield, F.J.; Ciccarelli, N.J.; Rosenberg, B.; DiNubile, M.J.; Janmey, P.A.; Margulies, S.S. Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine 2011, 54, 235–238. [CrossRef] [PubMed]
87. Yang, Z.; Chiou, T.T.; Stossel, T.P.; Kobzik, L. Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage nos3 function. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 309, L11–L16. [CrossRef] [PubMed]
88. Hirko, A.C.; Meyer, E.M.; King, M.A.; Hughes, J.A. Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of alzheimer’s disease. Mol. Ther. 2007, 15, 1623–1629. [CrossRef] [PubMed]
89. Matsuoka, Y.; Saito, M.; LaFrancois, J.; Gaynor, K.; Olm, V.; Wang, L.; Casey, E.; Lu, Y.; Shiratori, C.; Lemere, C.; et al. Novel therapeutic approach for the treatment of alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 2003, 23, 29–33. [CrossRef] [PubMed]
90. Smith, D.B.; Janmey, P.A.; Lind, S.E. Circulating actin-gelsolin complexes following oleic acid-induced lung injury. Am. J. Pathol. 1988, 130, 261–267. [PubMed]
91. Lind, S.E.; Smith, D.B.; Janmey, P.A.; Stossel, T.P. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am. Rev. Respir. Dis. 1988, 138, 429–434. [CrossRef] [PubMed]
92. Becker, P.M.; Kazi, A.A.; Wadgaonkar, R.; Pearse, D.B.; Kwiatkowski, D.; Garcia, J.G. Pulmonary vascular permeability and ischemic injury in gelsolin-deficient mice. Am. J. Respir. Cell. Mol. Biol. 2003, 28, 478–484. [CrossRef] [PubMed]
93. Degoricija, V.; Sharma, M.; Legac, A.; Gradiser, M.; Sefer, S.; Vucicević, Z. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: Impact of intensive care unit performance and antimicrobial therapy. Croat. Med. J. 2006, 47, 385–397. [PubMed]
94. Gullo, A.; Bianco, N.; Berlot, G. Management of severe sepsis and septic shock: Challenges and recommendations. Crit. Care Clin. 2006, 22, 489–501. [CrossRef] [PubMed]
95. Pierrakos, C.; Vincent, J.L. Sepsis biomarkers: A. review. Crit. Care 2010, 14, R15. [CrossRef] [PubMed]
96. Schmit, X.; Vincent, J.L. The time course of blood c-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection 2008, 36, 213–219. [CrossRef] [PubMed]
97. Durnaś, B.; Piktel, E.; Wątek, M.; Wollny, T.; Góźdź, S.; Smok-Kalwat, J.; Niemirowicz, K.; Savage, P.B.; Bucki, R. Anaerobic bacteria growth in the presence of cathelicidin ll-37 and selected ceragenins delivered as magnetic nanoparticles cargo. BMC Microbiol. 2017, 17, 167. [CrossRef] [PubMed]
98. Durnaś, B.; Wątek, M.; Wollny, T.; Niemirowicz, K.; Marzec, M.; Bucki, R.; Góźdź, S. Utility of blood procalcitonin concentration in the management of cancer patients with infections. Onco. Targets. Ther. 2016, 9, 469–475. [PubMed]
99. Dellinger, R.P.; Levy, M.M.; Rhodes, A.; Annane, D.; Gerlach, H.; Opal, S.M.; Sevransky, J.E.; Sprung, C.L.; Douglas, I.S.; Jaeschke, R.; et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 2013, 41, 580–637. [CrossRef] [PubMed]
100. Clyne, B.; Olshaker, J.S. The c-reactive protein. J. Emerg. Med. 1999, 17, 1019–1025. [CrossRef]
101. Tang, B.M.; Eslick, G.D.; Craig, J.C.; McLean, A.S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis. Lancet. Infect. Dis. 2007, 7, 210–217. [CrossRef]
102. Horváth-Szalai, Z.; Kustán, P.; Mühl, D.; Ludány, A.; Bugyi, B.; Kőszegi, T. Antagonistic sepsis markers: Serum gelsolin and actin/gelsolin ratio. Clin. Biochem. 2017, 50, 127–133. [CrossRef] [PubMed]
103. Huang, S.; Rhoads, S.L.; DiNubile, M.J. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clin. Infect. Dis. 1997, 24, 951–954. [CrossRef] [PubMed]
104. Horváth-Szalai, Z.; Kustán, P.; Szirmay, B.; Lakatos, Á.; Christensen, P.H.; Huber, T.; Bugyi, B.; Mühl, D.; Ludány, A.; Miseta, A.; et al. Validation of an automated immune turbidimetric assay for serum gelsolin and its possible clinical utility in sepsis. J. Clin. Lab. Anal. 2017. [CrossRef] [PubMed]
105. Horváth-Szalai, Z.; Kustán, P.; Szirmay, B.; Lakatos, Á.; Christensen, P.H.; Huber, T.; Bugyi, B.; Mühl, D.; Ludány, A.; Miseta, A.; et al. Predictive value of serum gelsolin and gc globulin in sepsis—A pilot study. Clin. Chem. Lab. Med. 2018. [CrossRef] [PubMed]
106. Bucki, R.; Pastore, J.J.; Randhawa, P.; Vegners, R.; Weiner, D.J.; Janmey, P.A. Antibacterial activities of rhodamine b-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin ll37, magainin ii, and melittin. Antimicrob. Agents Chemother. 2004, 48, 1526–1533. [CrossRef] [PubMed]
107. Bucki, R.; Georges, P.C.; Espinassous, Q.; Funaki, M.; Pastore, J.J.; Chaby, R.; Janmey, P.A. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 2005, 44, 9590–9597. [CrossRef] [PubMed]
108. Bucki, R.; Janmey, P.A. Interaction of the gelsolin-derived antibacterial pbp 10 peptide with lipid bilayers and cell membranes. Antimicrob. Agents Chemother. 2006, 50, 2932–2940. [CrossRef] [PubMed]
109. Guha, M.; Mackman, N. Lps induction of gene expression in human monocytes. Cell. Signal. 2001, 13, 85–94. [CrossRef]
110. Cheng, Y.; Hu, X.; Liu, C.; Chen, M.; Wang, J.; Wang, M.; Gao, F.; Han, J.; Zhang, C.; Sun, D.; et al. Gelsolin inhibits the inflammatory process induced by lps. Cell. Physiol. Biochem. 2017, 41, 205–212. [CrossRef] [PubMed]
111. Beutler, B.; Poltorak, A. Sepsis and evolution of the innate immune response. Crit. Care Med. 2001, 29, S2–S6. [CrossRef]
112. Serrander, L.; Skarman, P.; Rasmussen, B.; Witke, W.; Lew, D.P.; Krause, K.H.; Stendahl, O.; Nüsse, O. Selective inhibition of igg-mediated phagocytosis in gelsolin-deficient murine neutrophils. J. Immunol. 2000, 165, 2451–2457. [CrossRef] [PubMed]
113. Arora, P.D.; Glogauer, M.; Kapus, A.; Kwiatkowski, D.J.; McCulloch, C.A. Gelsolin mediates collagen phagocytosis through a rac-dependent step. Mol. Biol. Cell. 2004, 15, 588–599. [CrossRef] [PubMed]
114. Ordija, C.M.; Chiou, T.T.; Yang, Z.; Deloid, G.M.; de Oliveira Valdo, M.; Wang, Z.; Bedugnis, A.; Noah, T.L.; Jones, S.; Koziel, H.; et al. Free actin impairs macrophage bacterial defenses via scavenger receptor marco interaction with reversal by plasma gelsolin. Am. J. Physiol Lung Cell. Mol. Physiol 2017, 312, L1018–L1028. [CrossRef] [PubMed]
115. Argun, M.; Baykan, A.; Narin, F.; Özyurt, A.; Pamukçu, Ö.; Elmalı, F.; Üzüm, K.; Narin, N. Plasma gelsolin as a biomarker of acute rheumatic carditis. Cardiol. Young 2015, 25, 1276–1280. [CrossRef] [PubMed]
116. Wen, J.J.; Garg, N.J. Proteome expression and carbonylation changes during trypanosoma cruzi infection and chagas disease in rats. Mol. Cell. Proteom. 2012, 11, M111.010918. [CrossRef] [PubMed]
117. Yang, Z.; Levinson, S.; Stossel, T.; DiNubile, M.; Kobzik, L. Delayed therapy with plasma gelsolin improves survival in murine pneumococcal pneumonia. Open Forum Infect. Dis. 2017, 474–475. [CrossRef]
118. García-Expósito, L.; Ziglio, S.; Barroso-González, J.; de Armas-Rillo, L.; Valera, M.S.; Zipeto, D.; Machado, J.D.; Valenzuela-Fernández, A. Gelsolin activity controls efficient early hiv-1 infection. Retrovirology 2013, 10, 39. [CrossRef] [PubMed]
119. Qiao, H.; McMillan, J.R. Gelsolin segment 5 inhibits hiv-induced t-cell apoptosis via vpr-binding to vdac. FEBS Lett. 2007, 581, 535–540. [CrossRef] [PubMed]
120. Liu, H.; Liu, J.; Liang, S.; Xiong, H. Plasma gelsolin protects hiv-1 gp120-induced neuronal injury via voltage-gated k+ channel kv2.1. Mol. Cell. Neurosci. 2013, 57, 73–82. [CrossRef] [PubMed]
121. Boukli, N.M.; Shetty, V.; Cubano, L.; Ricaurte, M.; Coelho-Dos-Reis, J.; Nickens, Z.; Shah, P.; Talal, A.H.; Philip, R.; Jain, P. Unique and differential protein signatures within the mononuclear cells of hiv-1 and hcv mono-infected and co-infected patients. Clin. Proteom. 2012, 9, 11. [CrossRef] [PubMed]
122. Whitby, P.W.; Dick, H.L.; Campbell, P.W.; Tullis, D.E.; Matlow, A.; Stull, T.L. Comparison of culture and pcr for detection of burkholderia cepacia in sputum samples of patients with cystic fibrosis. J. Clin. Microbiol. 1998, 36, 1642–1645. [PubMed]
123. DENTON, R. Bronchial obstruction in cystic fibrosis: Rheological factors. Pediatrics 1960, 25, 611–620. [PubMed]
124. Bucki, R.; Byfield, F.J.; Janmey, P.A. Release of the antimicrobial peptide ll-37 from dna/f-actin bundles in cystic fibrosis sputum. Eur. Respir. J. 2007, 29, 624–632. [CrossRef] [PubMed]
125. Bucki, R.; Cruz, K.; Pogoda, K.; Eggert, A.; Chin, L.; Ferrin, M.; Imbesi, G.; Hadjiliadis, D.; Janmey, P.A. Enhancement of pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin. J. Cyst. Fibros. 2015, 14, 587–593. [CrossRef] [PubMed]
126. Walker, T.S.; Tomlin, K.L.; Worthen, G.S.; Poch, K.R.; Lieber, J.G.; Saavedra, M.T.; Fessler, M.B.; Malcolm, K.C.; Vasil, M.L.; Nick, J.A. Enhanced pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect. Immun. 2005, 73, 3693–3701. [CrossRef] [PubMed]
127. Straub, R.H.; Schradin, C. Chronic inflammatory systemic diseases: An evolutionary trade-off between acutely beneficial but chronically harmful programs. Evol. Med. Public Health 2016, 2016, 37–51. [CrossRef] [PubMed]
128. Kang, M.J.; Park, Y.J.; You, S.; Yoo, S.A.; Choi, S.; Kim, D.H.; Cho, C.S.; Yi, E.C.; Hwang, D.; Kim, W.U. Urinary proteome profile predictive of disease activity in rheumatoid arthritis. J. Proteome Res. 2014, 13, 5206–5217. [CrossRef] [PubMed]
129. Hu, Y.; Li, H.; Li, W.H.; Meng, H.X.; Fan, Y.Z.; Li, W.J.; Ji, Y.T.; Zhao, H.; Zhang, L.; Jin, X.M.; et al. The value of decreased plasma gelsolin levels in patients with systemic lupus erythematosus and rheumatoid arthritis in diagnosis and disease activity evaluation. Lupus 2013, 22, 1455–1461. [CrossRef] [PubMed]
130. Genre, F.; López-Mejías, R.; Miranda-Filloy, J.A.; Ubilla, B.; Carnero-López, B.; Gómez-Acebo, I.; Blanco, R.; Ochoa, R.; Rueda-Gotor, J.; González-Juanatey, C.; et al. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-tnf-alpha therapy. Clin. Exp. Rheumatol 2014, 32, 218–224. [PubMed]
131. Janciauskiene, S.; Olejnicka, B.; Koczulla, R.; Cardell, L.O.; Welte, T.; Westin, U. Allergen-specific immunotherapy increases plasma gelsolin levels. Am. J. Rhinol. Allergy. 2014, 28, e136–e140. [CrossRef] [PubMed]
132. Kandur, Y.; Çelik, A.; Gözübenli, F.; Çetinkaya, A.; Olgar, Ş. Plasma gelsolin as a potential biomarker for henoch-schoenlein purpura. Scand. J. Rheumatol. 2017, 46, 166–168. [CrossRef] [PubMed]
133. Endres, M.; Fink, K.; Zhu, J.; Stagliano, N.E.; Bondada, V.; Geddes, J.W.; Azuma, T.; Mattson, M.P.; Kwiatkowski, D.J.; Moskowitz, M.A. Neuroprotective effects of gelsolin during murine stroke. J. Clin. Investig. 1999, 103, 347–354. [CrossRef] [PubMed]
134. Carro, E. Gelsolin as therapeutic target in alzheimer’s disease. Expert Opin. Ther. Targets 2010, 14, 585–592. [CrossRef] [PubMed]
135. Pan, J.W.; He, L.N.; Xiao, F.; Shen, J.; Zhan, R.Y. Plasma gelsolin levels and outcomes after aneurysmal subarachnoid hemorrhage. Crit. Care 2013, 17, R149. [CrossRef] [PubMed]
136. Yildirim, F.; Gertz, K.; Kronenberg, G.; Harms, C.; Fink, K.B.; Meisel, A.; Endres, M. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp. Neurol. 2008, 210, 531–542. [CrossRef] [PubMed]
137. Chauhan, V.; Ji, L.; Chauhan, A. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in alzheimer’s disease. Biogerontology 2008, 9, 381–389. [CrossRef] [PubMed]
138. Kothakota, S.; Azuma, T.; Reinhard, C.; Klippel, A.; Tang, J.; Chu, K.; McGarry, T.J.; Kirschner, M.W.; Koths, K.; Kwiatkowski, D.J.; et al. Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science 1997, 278, 294–298. [CrossRef] [PubMed]
139. Chauhan, V.P.; Ray, I.; Chauhan, A.; Wisniewski, H.M. Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochem. Biophys. Res. Commun. 1999, 258, 241–246. [CrossRef] [PubMed]
140. Qiao, H.; Koya, R.C.; Nakagawa, K.; Tanaka, H.; Fujita, H.; Takimoto, M.; Kuzumaki, N. Inhibition of alzheimer’s amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol. Aging 2005, 26, 849–855. [CrossRef] [PubMed]
141. McDonagh, B.; Sheehan, D. Effect of oxidative stress on protein thiols in the blue mussel mytilus edulis: Proteomic identification of target proteins. Proteomics 2007, 7, 3395–3403. [CrossRef] [PubMed]
142. Güntert, A.; Campbell, J.; Saleem, M.; O’Brien, D.P.; Thompson, A.J.; Byers, H.L.; Ward, M.A.; Lovestone, S. Plasma gelsolin is decreased and correlates with rate of decline in alzheimer’s disease. J. Alzheimers Dis. 2010, 21, 585–596. [CrossRef] [PubMed]
143. Ji, L.; Chauhan, A.; Wegiel, J.; Essa, M.M.; Chauhan, V. Gelsolin is proteolytically cleaved in the brains of individuals with alzheimer’s disease. J. Alzheimers Dis. 2009, 18, 105–111. [CrossRef] [PubMed]
144. Manavalan, A.; Mishra, M.; Feng, L.; Sze, S.K.; Akatsu, H.; Heese, K. Brain site-specific proteome changes in aging-related dementia. Exp. Mol. Med. 2013, 45, e39. [CrossRef] [PubMed]
145. Donovan, L.E.; Dammer, E.B.; Duong, D.M.; Hanfelt, J.J.; Levey, A.I.; Seyfried, N.T.; Lah, J.J. Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for alzheimer’s disease. Alzheimers Res. Ther. 2013, 5, 32. [CrossRef] [PubMed]
146. Peng, M.; Jia, J.; Qin, W. Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for alzheimer disease. Neurosci. Lett. 2015, 595, 116–121. [CrossRef] [PubMed]
147. Bjelobaba, I.; Savic, D.; Lavrnja, I. Multiple sclerosis and neuroinflammation: The overview of current and prospective therapies. Curr. Pharm. Des. 2017, 23, 693–730. [CrossRef] [PubMed]
148. Forghani, R.; Wojtkiewicz, G.R.; Zhang, Y.; Seeburg, D.; Bautz, B.R.; Pulli, B.; Milewski, A.R.; Atkinson, W.L.; Iwamoto, Y.; Zhang, E.R.; et al. Demyelinating diseases: Myeloperoxidase as an imaging biomarker and therapeutic target. Radiology 2012, 263, 451–460. [CrossRef] [PubMed]
149. Park, S.M.; Hwang, I.K.; Kim, S.Y.; Lee, S.J.; Park, K.S.; Lee, S.T. Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics 2006, 6, 1192–1199. [CrossRef] [PubMed]
150. Kim, J.H.; Choi, Y.K.; Kwon, H.J.; Yang, H.K.; Choi, J.H.; Kim, D.Y. Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J. Gastroenterol. Hepatol. 2004, 19, 218–224. [CrossRef]
151. Yuan, X.; Wang, W.; Li, J.; Zheng, P.; Dong, P.; Chen, L.; Zhou, Y.; Xie, G.; Xu, D.; Liu, Y.; et al. Gelsolin suppresses gastric cancer metastasis through inhibition of pkr-p38 signaling. Oncotarget 2016, 7, 53459–53470. [CrossRef] [PubMed]
152. Litwin, M.; Mazur, A.J.; Nowak, D.; Mannherz, H.G.; Malicka-Błaszkiewicz, M. Gelsolin in human colon adenocarcinoma cells with different metastatic potential. Acta. Biochim. Pol. 2009, 56, 739–743. [PubMed]
153. Li, W.X.; Yang, M.X.; Hong, X.Q.; Dong, T.G.; Yi, T.; Lin, S.L.; Qin, X.Y.; Niu, W.X. Overexpression of gelsolin reduces the proliferation and invasion of colon carcinoma cells. Mol. Med. Rep. 2016, 14, 3059–3065. [CrossRef] [PubMed]
154. Ni, X.G.; Zhou, L.; Wang, G.Q.; Liu, S.M.; Bai, X.F.; Liu, F.; Peppelenbosch, M.P.; Zhao, P. The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol. Med. 2008, 14, 582–589. [CrossRef] [PubMed]
155. Thompson, C.C.; Ashcroft, F.J.; Patel, S.; Saraga, G.; Vimalachandran, D.; Prime, W.; Campbell, F.; Dodson, A.; Jenkins, R.E.; Lemoine, N.R.; et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007, 56, 95–106. [CrossRef] [PubMed]
156. Winston, J.S.; Asch, H.L.; Zhang, P.J.; Edge, S.B.; Hyland, A.; Asch, B.B. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res. Treat. 2001, 65, 11–21. [CrossRef] [PubMed]
157. Fan, N.J.; Gao, C.F.; Wang, C.S.; Lv, J.J.; Zhao, G.; Sheng, X.H.; Wang, X.L.; Li, D.H.; Liu, Q.Y.; Yin, J. Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in the chinese population: Examining differential protein expression using an itraq labelling-based proteomics approach. Can. J. Gastroenterol. 2012, 26, 41–47. [CrossRef] [PubMed]
158. Dosaka-Akita, H.; Hommura, F.; Fujita, H.; Kinoshita, I.; Nishi, M.; Morikawa, T.; Katoh, H.; Kawakami, Y.; Kuzumaki, N. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res. 1998, 58, 322–327. [PubMed]
159. Lee, H.K.; Driscoll, D.; Asch, H.; Asch, B.; Zhang, P.J. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999, 40, 14–19. [CrossRef]
160. Visapää, H.; Bui, M.; Huang, Y.; Seligson, D.; Tsai, H.; Pantuck, A.; Figlin, R.; Rao, J.Y.; Belldegrun, A.; Horvath, S.; et al. Correlation of ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003, 61, 845–850. [CrossRef]
161. Noske, A.; Denkert, C.; Schober, H.; Sers, C.; Zhumabayeva, B.; Weichert, W.; Dietel, M.; Wiechen, K. Loss of gelsolin expression in human ovarian carcinomas. Eur. J. Cancer 2005, 41, 461–469. [CrossRef] [PubMed]
162. Zhuo, J.; Tan, E.H.; Yan, B.; Tochhawng, L.; Jayapal, M.; Koh, S.; Tay, H.K.; Maciver, S.K.; Hooi, S.C.; Salto-Tellez, M.; et al. Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade. PLoS ONE 2012, 7, e43594. [CrossRef] [PubMed]
163. Yang, J.; Ramnath, N.; Moysich, K.B.; Asch, H.L.; Swede, H.; Alrawi, S.J.; Huberman, J.; Geradts, J.; Brooks, J.S.; Tan, D. Prognostic significance of mcm2, ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer 2006, 6, 203. [CrossRef] [PubMed]
164. Deng, R.; Hao, J.; Han, W.; Ni, Y.; Huang, X.; Hu, Q. Gelsolin regulates proliferation, apoptosis, migration and invasion in human oral carcinoma cells. Oncol. Lett. 2015, 9, 2129–2134. [CrossRef] [PubMed]
165. De Corte, V.; Bruyneel, E.; Boucherie, C.; Mareel, M.; Vandekerckhove, J.; Gettemans, J. Gelsolin-induced epithelial cell invasion is dependent on ras-rac signaling. EMBO J. 2002, 21, 6781–6790. [CrossRef] [PubMed]
166. Bohgaki, M.; Matsumoto, M.; Atsumi, T.; Kondo, T.; Yasuda, S.; Horita, T.; Nakayama, K.I.; Okumura, F.; Hatakeyama, S.; Koike, T. Plasma gelsolin facilitates interaction between β2 glycoprotein i and α5β1 integrin. J. Cell. Mol. Med. 2011, 15, 141–151. [CrossRef] [PubMed]
167. Pierredon, S.; Ribaux, P.; Tille, J.C.; Petignat, P.; Cohen, M. Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight. Oncol. Lett. 2017, 13, 4965–4973. [CrossRef] [PubMed]
168. Lokamani, I.; Looi, M.L.; Md Ali, S.A.; Mohd Dali, A.Z.; Ahmad Annuar, M.A.; Jamal, R. Gelsolin and ceruloplasmin as potential predictive biomarkers for cervical cancer by 2d-dige proteomics analysis. Pathol. Oncol. Res. 2014, 20, 119–129. [CrossRef] [PubMed]
169. Chen, R.; Brentnall, T.A.; Pan, S.; Cooke, K.; Moyes, K.W.; Lane, Z.; Crispin, D.A.; Goodlett, D.R.; Aebersold, R.; Bronner, M.P. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell. Proteom. 2007, 6, 1331–1342. [CrossRef] [PubMed]
170. Lowenfels, A.B.; Maisonneuve, P.; Cavallini, G.; Ammann, R.W.; Lankisch, P.G.; Andersen, J.R.; Dimagno, E.P.; Andrén-Sandberg, A.; Domellöf, L. Pancreatitis and the risk of pancreatic cancer. International pancreatitis study group. N. Engl. J. Med. 1993, 328, 1433–1437. [CrossRef] [PubMed]
171. Van den Abbeele, A.; De Corte, V.; Van Impe, K.; Bruyneel, E.; Boucherie, C.; Bracke, M.; Vandekerckhove, J.; Gettemans, J. Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett. 2007, 255, 57–70. [CrossRef] [PubMed]
172. Panis, C.; Pizzatti, L.; Bufalo, A.C.; Herrera, A.C.; Victorino, V.J.; Cecchini, R.; Abdelhay, E. Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer. Tumour Biol. 2016, 37, 3775–3783. [CrossRef] [PubMed]
173. Jayapalan, J.J.; Lee, C.S.; Lee, C.C.; Ng, K.L.; Junit, S.M.; Hashim, O.H. Itraq analysis of urinary proteins: Potential use of gelsolin and osteopontin to distinguish benign thyroid goiter from papillary thyroid carcinoma. Clin. Biochem. 2018. [CrossRef] [PubMed]
174. Wang, Z.; Wen, L.; Ma, X.; Chen, Z.; Yu, Y.; Zhu, J.; Wang, Y.; Liu, Z.; Liu, H.; Wu, D.; et al. High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients. Glycobiology 2012, 22, 930–938. [CrossRef] [PubMed]
175. Kułakowska, A.; Byfield, F.J.; Zendzian-Piotrowska, M.; Zajkowska, J.M.; Drozdowski, W.; Mroczko, B.; Janmey, P.A.; Bucki, R. Increased levels of sphingosine-1-phosphate in cerebrospinal fluid of patients diagnosed with tick-borne encephalitis. J. Neuroinflamm. 2014, 11, 193. [CrossRef] [PubMed]
176. Wątek, M.; Durnaś, B.; Wollny, T.; Pasiarski, M.; Góźdź, S.; Marzec, M.; Chabowska, A.; Wolak, P.; Żendzian-Piotrowska, M.; Bucki, R. Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia. Lipids Health Dis. 2017, 16, 235. [CrossRef] [PubMed]
177. Lee, P.S.; Bhan, I.; Thadhani, R. The potential role of plasma gelsolin in dialysis-related protein-energy wasting. Blood Purif. 2010, 29, 99–101. [CrossRef] [PubMed]
178. Chellaiah, M.; Hruska, K. Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase. Mol. Biol Cell. 1996, 7, 743–753. [CrossRef] [PubMed]
179. Tomas, A.; Yermen, B.; Min, L.; Pessin, J.E.; Halban, P.A. Regulation of pancreatic beta-cell insulin secretion by actin cytoskeleton remodelling: Role of gelsolin and cooperation with the mapk signalling pathway. J. Cell. Sci. 2006, 119, 2156–2167. [CrossRef] [PubMed]
180. Yermen, B.; Tomas, A.; Halban, P.A. Pro-survival role of gelsolin in mouse beta-cells. Diabetes 2007, 56, 80–87. [CrossRef] [PubMed]
181. Kalwat, M.A.; Wiseman, D.A.; Luo, W.; Wang, Z.; Thurmond, D.C. Gelsolin associates with the n terminus of syntaxin 4 to regulate insulin granule exocytosis. Mol. Endocrinol. 2012, 26, 128–141. [CrossRef] [PubMed]
182. Bouillon, R.; van Baelen, H.; de Moor, P. The measurement of the vitamin d-binding protein in human serum. J. Clin. Endocrinol. Metab. 1977, 45, 225–231. [CrossRef] [PubMed]
183. Garg, R.; Peddada, N.; Dolma, K.; Khatri, N.; Ashish, A. Pregnancy related hormones, progesterone and human chorionic gonadotrophin, upregulate expression of maternal plasma gelsolin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2018. [CrossRef] [PubMed]
184. Zhang, Y.; Kang, Y.; Zhou, Q.; Zhou, J.; Wang, H.; Jin, H.; Liu, X.; Ma, D.; Li, X. Quantitative proteomic analysis of serum from pregnant women carrying a fetus with conotruncal heart defect using isobaric tags for relative and absolute quantitation (itraq) labeling. PLoS ONE 2014, 9, e111645. [CrossRef] [PubMed]
185. Anagnostopoulos, A.K.; Kolialexi, A.; Mavrou, A.; Vougas, K.; Papantoniou, N.; Antsaklis, A.; Kanavakis, E.; Fountoulakis, M.; Tsangaris, G.T. Proteomic analysis of amniotic fluid in pregnancies with klinefelter syndrome foetuses. J. Proteom. 2010, 73, 943–950. [CrossRef] [PubMed]
186. Kolla, V.; Jenö, P.; Moes, S.; Tercanli, S.; Lapaire, O.; Choolani, M.; Hahn, S. Quantitative proteomics analysis of maternal plasma in down syndrome pregnancies using isobaric tagging reagent (itraq). J. Biomed. Biotechnol 2010, 2010, 952047. [CrossRef] [PubMed]
187. Auer, J.; Camoin, L.; Guillonneau, F.; Rigourd, V.; Chelbi, S.T.; Leduc, M.; Laparre, J.; Mignot, T.M.; Vaiman, D. Serum profile in preeclampsia and intra-uterine growth restriction revealed by itraq technology. J. Proteom. 2010, 73, 1004–1017. [CrossRef] [PubMed]
188. Redman, C.W.; Sargent, I.L. Latest advances in understanding preeclampsia. Science 2005, 308, 1592–1594. [CrossRef] [PubMed]
189. James, J.L.; Whitley, G.S.; Cartwright, J.E. Pre-eclampsia: Fitting together the placental, immune and cardiovascular pieces. J. Pathol. 2010, 221, 363–378. [CrossRef] [PubMed]
190. Ahmad, S.; Ahmed, A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 2004, 95, 884–891. [CrossRef] [PubMed]
191. Goswami, D.; Tannetta, D.S.; Magee, L.A.; Fuchisawa, A.; Redman, C.W.; Sargent, I.L.; von Dadelszen, P. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 2006, 27, 56–61. [CrossRef] [PubMed]
192. Haverland, N.; Pottiez, G.; Wiederin, J.; Ciborowski, P. Immunoreactivity of anti-gelsolin antibodies: Implications for biomarker validation. J. Transl. Med. 2010, 8, 137. [CrossRef] [PubMed]
193. Fock, U.; Jockusch, B.M.; Schubert, W.D.; Hinssen, H. Topological assignment of the n-terminal extension of plasma gelsolin to the gelsolin surface. Biochem. J. 2005, 385, 659–665. [CrossRef] [PubMed]
194. Lee, P.S.; Waxman, A. The importance of differentiating gelsolin isoforms. Am. J. Respir. Crit. Care Med. 2006, 173, 685, author reply 685. [CrossRef] [PubMed]
195. Saraswat, M.; Joenväärä, S.; Seppänen, H.; Mustonen, H.; Haglund, C.; Renkonen, R. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis. Cancer Med. 2017, 6, 1738–1751. [CrossRef] [PubMed]